Tvardi Therapeutics, Inc. (TVRD) Key Metrics
TVRD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $13.5M
- Enterprise value
- $1.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 559.6
- Price / book
- 2.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
TVRD key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTVRD valuation Price multiples at each fiscal year-end price.
TVRD returns How much profit the business earns on the capital it uses.
TVRD per-share figures Results divided by the shares outstanding at year-end.
TVRD financial health Debt, liquidity and how easily interest is covered.
TVRD efficiency & capital use Working capital cycle and where the cash goes.
TVRD valuation history
TVRD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TVRD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TVRD price vs earnings per share
TVRD key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $33.5M | — | $250.2M | $3.62B | — | — |
| Enterprise value | $2.9M | — | $227.7M | $3.58B | — | — |
| Price / sales | — | — | 11.9 | 86.4 | — | — |
| Price / book | 1.6 | — | — | — | — | — |
| EV / sales | — | — | 10.9 | 85.4 | — | — |
| Earnings yield | −54.4% | — | −47.4% | −2.4% | — | — |
| Free cash flow yield | −70.2% | — | −37.7% | −0.5% | — | — |
| Share price at fiscal year-end | $4.30 | $18.36 | $26.75 | $386.64 | $438.48 | $544.68 |
| Per share | ||||||
| Revenue per share | $0.00 | — | $2.24 | $4.48 | — | — |
| Earnings per share | −$2.34 | — | −$12.67 | −$9.14 | — | — |
| Operating cash flow per share | −$3.02 | — | −$9.84 | −$1.91 | — | — |
| Free cash flow per share | −$3.02 | — | −$10.10 | −$1.92 | — | — |
| Cash per share | $3.96 | — | $2.45 | $4.68 | — | — |
| Book value per share | $2.69 | — | −$6.63 | −$4.82 | — | — |
| Tangible book value per share | $2.65 | — | −$6.68 | −$4.87 | — | — |
| Capex per share | $0.00 | — | $0.25 | $0.01 | — | — |
| Debt per share | $0.03 | — | $0.04 | $0.25 | — | — |
| Shares outstanding | 7.8M | — | 9.4M | 9.4M | — | — |
| Change in shares outstanding | — | — | 0.0% | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −222.8% | — | — | — | −37.1% | 3.4% |
| Return on invested capital (ROIC) | — | — | — | — | −102.4% | 7.3% |
| Return on assets (ROA) | −48.0% | −200.1% | −328.8% | −58.5% | −34.1% | 3.1% |
| Return on tangible assets | −57.4% | −163.1% | −446.3% | −191.7% | −35.8% | 3.1% |
| Free cash flow margin | — | −868.2% | −450.5% | −42.8% | −261.1% | −4.3% |
| Income quality (OCF / net income) | — | — | — | — | — | −0.65 |
| Financial health | ||||||
| Total debt | $201,000 | $44.4M | $368,000 | $2.4M | $3.7M | $5.3M |
| Cash & short-term investments | $30.8M | $37.9M | $22.9M | $43.7M | $167.0M | $180.9M |
| Net debt | −$30.6M | $6.5M | −$22.6M | −$41.4M | −$163.4M | −$175.7M |
| Debt / equity | 0.01 | — | — | — | 0.02 | 0.02 |
| Debt / assets | 0.01 | 1.01 | 0.01 | 0.05 | 0.01 | 0.02 |
| Net debt / EBITDA | — | — | — | — | — | −20.11 |
| Current ratio | 2.86 | 11.03 | 7.97 | 10.31 | 9.84 | 10.55 |
| Quick ratio | 2.86 | 10.81 | 7.97 | 10.31 | 9.69 | 10.55 |
| Interest coverage | — | -6.6 | — | — | — | — |
| Working capital | $20.5M | $39.9M | $22.9M | $39.8M | $155.7M | $176.6M |
| Invested capital | −$9.7M | $2.0M | −$84.6M | −$86.4M | $64.2M | $73.4M |
| Tangible asset value | $20.6M | −$5.0M | −$62.5M | −$45.6M | $227.5M | $249.0M |
| Net current asset value | $20.4M | −$4.6M | −$62.9M | −$46.0M | $153.8M | $172.9M |
| Graham net-net per share | $2.53 | — | −$6.75 | −$4.60 | — | — |
| Capital allocation | ||||||
| Capex / revenue | — | 14.7% | 11.3% | 0.1% | 0.2% | 0.3% |
| Capex / depreciation | 0.00 | 5.45 | 9.17 | 0.59 | 0.03 | 0.34 |
| Stock-based compensation / revenue | — | 4.5% | 1.5% | 0.6% | — | — |
| R&D / revenue | — | 458.9% | 516.9% | 219.2% | 358.6% | 79.8% |
| SG&A / revenue | — | 62.4% | 13.3% | 6.5% | — | — |
| Efficiency | ||||||
| Days sales outstanding | — | 217.7 | 73.7 | 24.4 | 25.5 | 5.6 |
| Days of inventory on hand | — | 404.6 | — | — | 606.9 | — |
| Days payables outstanding | 8,938.7 | 684.4 | 114.0 | 195.1 | 1,235.2 | — |
| Cash conversion cycle (days) | — | -62.2 | -40.3 | -170.7 | -602.8 | — |
| Receivables turnover | — | 1.68 | 4.95 | 14.94 | 14.32 | 65.45 |
| Payables turnover | 0.04 | 0.53 | 3.20 | 1.87 | 0.30 | — |
| Inventory turnover | — | 0.90 | — | — | 0.60 | — |
| Asset turnover | 0.00 | 0.20 | 0.58 | 0.29 | 0.09 | 0.50 |
| Average receivables | — | $4.3M | $4.2M | $2.8M | $1.6M | $2.1M |
| Average payables | $2.3M | $1.5M | $2.0M | $4.0M | $5.3M | $4.9M |
| Average inventory | — | $900,000 | — | — | $2.6M | — |
| Intangibles / total assets | 1.0% | 0.9% | 1.7% | 1.1% | 0.0% | 0.0% |
Computed from TVRD's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TVRD valuation and financial ratios
Tvardi Therapeutics earned a return on equity of −222.8% in fiscal 2025. It ended the year with $0.2 million of debt and $30.8 million in cash and short-term investments, a net cash position of $30.6 million.
See the TVRD income statement, the TVRD chart for price history, or the TVRD stock overview for the latest quote and news.
TVRD key metrics FAQ
What is Tvardi Therapeutics's return on equity?
Tvardi Therapeutics's return on equity (ROE) was −222.8% in fiscal 2025: net income of -$18.2 million on average shareholders' equity of $8.2 million.
How much debt does Tvardi Therapeutics have?
Tvardi Therapeutics had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Tvardi Therapeutics's free cash flow yield?
Tvardi Therapeutics generated -$23.5 million of free cash flow in fiscal 2025, a free cash flow yield of −70.2% on its market value at year-end ($33.5 million).
What is Tvardi Therapeutics's current ratio?
Tvardi Therapeutics's current ratio was 2.86 at the end of fiscal 2025: current assets were 2.86 times current liabilities.